← Back to Search

Remote Assessment Technology for Multiple Sclerosis

Phase 2

Waitlist Available

Research Sponsored by Transparency Life Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Males and females between the ages of 18 and 64

Baseline score of 0-5.5 on Kurtzke's Expanded Disability Status Scale (EDSS)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 6

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether the MSFC can be done at home using video conferencing technology.

Who is the study for?

Adults aged 18-64 with a documented diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and an EDSS score between 0-5.5 can join this trial. They must have normal blood pressure, not be too low or high, and someone at home to help during tests. People with very low/high blood pressure or slow heart rate (<50 bpm) cannot participate.

What is being tested?

The study is testing the use of the Multiple Sclerosis Functional Composite (MSFC), both at a study site and remotely from home using technology like video calls. This is to prepare for a future phase 2 trial evaluating lisinopril in treating multiple sclerosis.

What are the potential side effects?

Since this stage of the trial focuses on calibrating assessment tools rather than medication effects, specific side effects are not detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 64 years old.

Select...

My disability level is moderate, as measured by a specific scale.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 6

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 6

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

MSFC Score Comparison

Mobile 9-hole Peg Test Time Comparison

Mobile Paced Auditory Serial Addition Test Score Comparison

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: Group 2Active Control2 Interventions

Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.

Group II: Group 1Active Control2 Interventions

0 / 2Eligibility criteria met